**Secondary negative symptoms across schizophrenia and bipolar disorder**

Supplement

Table S1. DSM IV criteria of patients

|  |  |
| --- | --- |
| DSM IV code | Number of subjects |
| 295.10 Schizophrenia, Disorganized Type | 1 |
| 295.30 Schizophrenia, Paranoid Type | 21 |
| 295.60 Schizophrenia, Residual Type | 6 |
| 295.70 Schizoaffective Disorder | 11 |
| 295.90 Schizophrenia, Undifferentiated Type | 11 |
| 296.40 Bipolar I Disorder, Most Recent Episode Hypomanic | 4 |
| 296.41 Bipolar I Disorder, Most Recent Episode Manic, Mild | 2 |
| 296.42 Bipolar I Disorder, Most Recent Episode Manic, Moderate | 1 |
| 296.45 Bipolar I Disorder, Most Recent Episode Manic, In Partial Remission | 3 |
| 296.46 Bipolar I Disorder, Most Recent Episode Manic, In Full Remission | 6 |
| 296.51 Bipolar I Disorder, Most Recent Episode Depressed, Mild | 2 |
| 296.52 Bipolar I Disorder, Most Recent Episode Depressed, Moderate | 4 |
| 296.53 Bipolar I Disorder, Most Recent Episode Depressed, Severe Without Psychotic Features | 5 |
| 296.55 Bipolar I Disorder, Most Recent Episode Depressed, In Partial Remission | 8 |
| 296.56 Bipolar I Disorder, Most Recent Episode Depressed, In Full Remission | 5 |
| 296.62 Bipolar I Disorder, Most Recent Episode Mixed, Moderate | 1 |
| 296.64 Bipolar I Disorder, Most Recent Episode Mixed, Severe With Psychotic Features | 3 |
| 296.7 Bipolar I Disorder, Most Recent Episode Unspecified | 5 |

Table S2. Specific mood stabilizer intake

|  |  |  |
| --- | --- | --- |
|  | SCZ | BD-I |
| Lithium | 5 | 9 |
| Valproate | 5 | 9 |
| Lamotrigine | 2 | 10 |
| Topiramate | 1 | 6 |
| Oxcarbazepin | - | 5 |
| Carbamazepine | 1 | 1 |
| Gabapentine | 0 | 1 |

Table S3: Model fit and negative symptom dimensions scores and potential sources of secondary negative symptoms all over schizophrenia and bipolar disorder

|  |  |  |
| --- | --- | --- |
|  | Beta [95% CI] | |
| Amotivation | Diminished expression |
| Group | -0.26 (-2.84; 0.14) (\*) | -0.31 (-2.46; 0) (\*) |
| Age | 0.06 (-0.03; 0.07) | -0.11 (-0.07; 0.02) |
| Sex | 0.05 (-0.8; 1.33) | 0.09 (-0.48; 1.26) |
| Positive Symptoms. | -0.03 (-0.28; 0.22) | 0.07 (-0.16; 0.26) |
| Disorganization | 0.37 (0.21; 0.72)\*\*\* | 0.07 (-0.14; 0.28) |
| Depression | 0.25 (0.01; 0.13)\* | 0.1 (-0.03; 0.07) |
| RSP-eq dose | 0.12 (-0.02; 0.08) | 0.21 (0; 0.08)\*\* |
| MS intake | 0.06 (-0.73; 1.39) | -0.02 (-0.96; 0.77) |

Table S4. Linear multivariate regressions of the two negative symptom dimensions as dependent variables with potential sources of secondary negative symptoms as independent variables for SCZ and BD-1 patients independently. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using the Scale for the assessment of positive symptoms (SAPS); Depressive symptoms were measured using the Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; MS intake, mood stabilizer intake as categorical factor (mood stabilizer intake yes or no); \*p<0.05 \*\*p<0.005 \*\*\*p<0.001

Table S4 Subgroup analyses of negative symptoms and potential sources of secondary negative symptoms in patients with SCZ and BD-I

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Beta [95% CI] | | | | | |
|  | Avolition-Apathy | Anhedonia-Asociality | Alogia | Blunted affect | Amotivation | Diminished expression |
| **Schizophrenia** |  |  |  |  |  |  |
| Age | 0.18 (-0.01; 0.08) | 0.13 (-0.03; 0.07) | -0.19 (-0.06; 0.02) | -0.03 (-0.05; 0.04) | 0.17 (-0.03; 0.13) | -0.11 (-0.11; 0.05) |
| Sex | -0.01 (-1.04; 1) | -0.12 (-1.49; 0.64) | 0.14 (-0.53; 1.29) | 0.07 (-0.83; 1.25) | -0.07 (-2.3; 1.41) | 0.11 (-1.21; 2.39) |
| Positive Symptoms. | -0.08 (-0.2; 0.12) | -0.04 (-0.19; 0.15) | 0.02 (-0.14; 0.15) | 0.07 (-0.13; 0.2) | -0.06 (-0.36; 0.24) | 0.05 (-0.25; 0.33) |
| Disorganization | 0.47 (0.12; 0.51)\*\* | 0.27 (-0.02; 0.38) | 0.16 (-0.09; 0.25) | -0.02 (-0.21; 0.18) | 0.41 (0.14; 0.84)\*\* | 0.07 (-0.27; 0.41) |
| Depression | 0.2 (-0.02; 0.08) | 0.33 (0; 0.11)\* | 0 (-0.04; 0.05) | 0.22 (-0.02; 0.08) | 0.29 (0; 0.18)(\*) | 0.13 (-0.06; 0.12) |
| RSP-eq dose | 0.1 (-0.03; 0.06) | 0.15 (-0.02; 0.07) | 0.21 (-0.01; 0.07) | 0.07 (-0.04; 0.06) | 0.14 (-0.04; 0.13) | 0.15 (-0.04; 0.12) |
| MS intake | 0.11 (-0.61; 1.38) | 0.09 (-0.69; 1.37) | -0.21 (-1.46; 0.3) | -0.08 (-1.28; 0.75) | 0.11 (-1.08; 2.53) | -0.16 (-2.59; 0.9) |
| **Bipolar Disorder** |  |  |  |  |  |  |
| Age | -0.14 (-0.08; 0.03) | 0.05 (-0.03; 0.05) | 0.22 (-0.01; 0.03) | -0.19 (-0.06; 0.01) | -0.06 (-0.1; 0.07) | -0.08 (-0.06; 0.04) |
| Sex | 0.02 (-0.85; 0.96) | 0.14 (-0.34; 1.02) | 0.18 (-0.11; 0.42) | 0.13 (-0.34; 0.9) | 0.12 (-0.87; 1.91) | 0.16 (-0.4; 1.28) |
| Positive Symptoms. | 0.14 (-0.42; 0.82) | -0.23 (-0.76; 0.18) | -0.44 (-0.37; -0.01)\* | 0.08 (-0.33; 0.52) | 0 (-0.96; 0.95) | -0.07 (-0.68; 0.48) |
| Disorganization | 0.21 (-0.12; 0.45) | 0.34 (0.02; 0.45)\* | 0.14 (-0.05; 0.12) | 0.18 (-0.09; 0.31) | 0.33 (-0.01; 0.87)(\*) | 0.18 (-0.13; 0.41) |
| Depression | 0.03 (-0.05; 0.06) | 0.46 (0.01; 0.1)\* | 0.22 (-0.01; 0.03) | 0.14 (-0.02; 0.06) | 0.21 (-0.04; 0.14) | 0.18 (-0.03; 0.08) |
| RSP-eq dose | 0.1 (-0.03; 0.06) | 0.04 (-0.03; 0.04) | -0.07 (-0.02; 0.01) | 0.43 (0.01; 0.07)\* | 0.09 (-0.05; 0.08) | 0.31 (0; 0.08)(\*) |
| MS intake | 0.02 (-1.01; 1.1) | 0.03 (-0.72; 0.88) | 0.45 (0.09; 0.7)\* | 0.07 (-0.57; 0.88) | -0.01 (-1.68; 1.57) | 0.2 (-0.43; 1.53) |

Table S3. Group specific linear regressions of negative symptoms and potential sources of secondary negative symptoms. Linear multivariate regressions of 4 negative symptom domains as dependent variables with potential sources of secondary negative symptoms as independent variables for SZ and BD-1 patients independently. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using the Scale for the assessment of positive symptoms (SAPS); Depressive symptoms were measured using the Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; MS intake, mood stabilizer intake as categorical factor (mood stabilizer intake yes or no); \*p<0.05 \*\*p<0.005 \*\*\*p<0.001

Table S5. Relationship between clinical variables and working memory

|  |  |  |  |
| --- | --- | --- | --- |
|  | Transdiagnostic | SZ | BD |
| Model fit | r2adj= .34  F(12,83) = 5.02\*\*\* | r2adj= .09  F(11,38) = 1.42 | r2adj= .20  F(11,34) = 2.04 |
| Group | 0.48 [1.28, 4.81]\*\* |  |  |
| Age | -0.32 [-0.18, -0.05]\*\*\* | -0.35 [-0.22, -0.01]\* | -0.44 [-0.24, -0.02]\* |
| Sex | 0.02 [-1.01, 1.35] | 0.05 [-1.90, 2.62] | -0.03 [-1.70, 1.42] |
| Avolition-Apathy | -0.34 [-1.21, -0.23]\*\* | -0.27 [-1.36, 0.31] | -0.52 [-1.66, -0.33]\*\* |
| Anhedonia -Asociality | 0.20 [-0.13, 1.02] | 0.04 [-0.79, 0.94] | 0.53 [0.17, 2.01]\* |
| Alogia | -0.13 [-1.25, 0.37] | -0.25 [-1.76, 0.45] | 0.07 [-2.72, 3.55] |
| Blunted affect | -0.01 [-0.63, 0.56] | 0.03 [-0.85, 1.00] | -0.09 [-1.57, 1.12] |
| Positive symptoms | 0.17 [-0.11, 0.48] | 0.10 [-0.25, 0.46] | 0.18 [-0.82, 1.78] |
| Disorganization | -0.00 [-0.31, 0.31] | 0.13 [-0.30, 0.64] | -0.16 [-0.74, 0.27] |
| Depression | -0.04 [-0.09, 0.06] | 0.09 [-0.10, 0.15] | -0.25 [-0.18, 0.05] |
| RSP-eq dose | -0.06 [-0.08, 0.04] | 0.10 [-0.07, 0.14] | -0.19 [-0.14, 0.05] |
| MS intake | -0.09 [-1.81, 0.64] | -0.24 [-3.96, 0.52] | -0.03 [-2.14, 1.87] |

Table S5. Linear regressions of negative symptom domains and other clinical variables as independent variables and working memory sum score as dependent variable across SZ and BD-1 patients. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using Scale for the assessment of positive symptoms (SAPS); depressive symptoms were measured using Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; MS intake, mood stabilizer intake as categorical factor (mood stabilizer intake yes or no); \*p<0.05 \*\*p<0.005 \*\*\*p<0.001